Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $638,000.

  • NewAmsterdam Pharma Co N.V's Change in Accured Expenses rose 58.71% to $638,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$482,000, marking a year-over-year increase of 92.59%. This contributed to the annual value of $1.7 million for FY2024, which is 69.18% down from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Change in Accured Expenses of $638,000 as of Q3 2025, which was down 55.66% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Change in Accured Expenses peaked at $9.3 million during Q3 2023, and registered a low of -$5.8 million during Q4 2023.
  • Its 3-year average for Change in Accured Expenses is $389,091, with a median of $402,000 in 2024.
  • Over the last 5 years, NewAmsterdam Pharma Co N.V's Change in Accured Expenses had its largest YoY gain of 431.00% in 2025, and its largest YoY loss of 258.65% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Change in Accured Expenses (Quarterly) stood at -$5.8 million in 2023, then spiked by 141.30% to $2.4 million in 2024, then spiked by 58.71% to $638,000 in 2025.
  • Its last three reported values are $638,000 in Q3 2025, $1.4 million for Q2 2025, and -$5.0 million during Q1 2025.